US EditionLucid Diagnostics Announces Pricing of Public Offering of Common Stock
- Lucid Diagnostics, a subsidiary of PAVmed Inc., announced a public offering of common stock on April 9, 2025.
- The company intends to use proceeds from the offering for working capital and other corporate needs.
- The offering involves 12,500,000 shares priced at $1.20 each, potentially generating $15 million before expenses.
- Underwriters have a 45-day option to buy 1,875,000 additional shares, less discounts; Canaccord Genuity is sole bookrunner.
- The offering, expected to close around April 11, 2025, is subject to market conditions and customary closing procedures.
Insights by Ground AI
Does this summary seem wrong?
36 Articles
36 Articles
All
Left
2
Center
13
Right
1
The Berkshire Eagle+17 Reposted by 17 other sources
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
NEW YORK, April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the pricing of its underwritten public offering of…
Coverage Details
Total News Sources36
Leaning Left2Leaning Right1Center13Last UpdatedBias Distribution81% Center
Bias Distribution
- 81% of the sources are Center
81% Center
13%
C 81%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
